Background: Lack of a global consensus on the definition of advanced Parkinson’s disease (APD) and considerations for timing of device-aided therapies may result in heterogeneity in care. Objectives: To reach consensus among movement disorder specialists regarding key patient characteristics indicating transition to APD and guiding appropriate use of device-aided therapies in the management of PD symptoms. Methods: A Delphi-panel approach was utilized to synthesize opinions of movement disorder specialists and build consensus. Results: A panel was comprised of movement disorder specialists from 10 European countries with extensive experience of treating PD patients (mean =24.8 ± 7.2 years). Consensus on indicators of suspected APD and eligi...
Objectives: To evaluate the proportion of Parkinson's disease (PD) patients identified as having adv...
Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second most commo...
Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second most commo...
To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To ...
Background: Frequency of Advanced Parkinson’s Disease (APD) and its clinical characteristics are sti...
To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To ...
To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To ...
Abstract Background There are currently no standard diagnostic criteria for characterizing advanced ...
Navigate PD was an educational program established to supplement existing guidelines and provide rec...
Navigate PD was an educational program established to supplement existing guidelines and provide rec...
AIMS OF THE STUDY Currently, the characterisation of advanced Parkinson’s disease (APD) d...
Altres ajuts: AbbVie Spain S.L.U., Avenida de Burgos, 91, 28050 Madrid, has given support to the Sci...
OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disord...
AbstractNavigate PD was an educational program established to supplement existing guidelines and pro...
Introduction: Standardized and validated criteria to define advanced Parkinson’s disease (PD) or ide...
Objectives: To evaluate the proportion of Parkinson's disease (PD) patients identified as having adv...
Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second most commo...
Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second most commo...
To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To ...
Background: Frequency of Advanced Parkinson’s Disease (APD) and its clinical characteristics are sti...
To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To ...
To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To ...
Abstract Background There are currently no standard diagnostic criteria for characterizing advanced ...
Navigate PD was an educational program established to supplement existing guidelines and provide rec...
Navigate PD was an educational program established to supplement existing guidelines and provide rec...
AIMS OF THE STUDY Currently, the characterisation of advanced Parkinson’s disease (APD) d...
Altres ajuts: AbbVie Spain S.L.U., Avenida de Burgos, 91, 28050 Madrid, has given support to the Sci...
OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disord...
AbstractNavigate PD was an educational program established to supplement existing guidelines and pro...
Introduction: Standardized and validated criteria to define advanced Parkinson’s disease (PD) or ide...
Objectives: To evaluate the proportion of Parkinson's disease (PD) patients identified as having adv...
Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second most commo...
Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second most commo...